Kazuo Tamura

Kazuo Tamura

Auto-generated profile, based on publicly available information

Kazuo Tamura

Division of Genetic Medicine, Master of Science, Graduate School of Science and Engineering Research, Kindai University, Osaka, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2019 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KTKazuo Tamura
Kazuo Tamura
MKMotohide Kaneda
Motohide Kaneda
MFMashu Futagawa
Mashu Futagawa
MTMiho Takeshita
Miho Takeshita
SKSanghyuk Kim
Sanghyuk Kim
JTJunko Tatsumi-Miyajima
Junko Tatsumi-Miyajima

1 December 2005 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
Xiaojun HuangXiaojun Huang
Xiaojun Huang
SZShen Zhixiang
Shen Zhixiang
WCWang Chun
Wang Chun
ARA. Harryanto Reksodiputro
A. Harryanto Reksodiputro
DRDody Ranuhardy
Dody Ranuhardy
JPJuan J. Picazo
Juan J. Picazo

1 May 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
MFMichinori Funato
Michinori Funato
YTYukiko Tsunematsu
Yukiko Tsunematsu
FYFumito Yamazaki
Fumito Yamazaki
CTChieko Tamura
Chieko Tamura
TKTadashi Kumamoto
Tadashi Kumamoto
KTKazuo Tamura
Kazuo Tamura
Li‐Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome, and the majority of patients with LFS have been identified with germline variants in the p53 tumor suppressor (TP53) gene. In the past three decades, considerable case reports of TP53 germline variants have been published in Japan. To the best of our knowledge, there have been no large‐scale studies of Japanese patients with LFS. In this study, we aimed to identify Japanese patients with TP53 germline variants and to reveal the characteristics of LFS in Japan. We collected reported cases by reviewing the medical literature and cases diagnosed at the institutions of the authors. We identified 68 individuals from 48 families with TP53 germline pathogenic or likely pathogenic variants. Of the 48 families, 35 (72.9%) had missense variants, most of which were located within the DNA‐binding loop. A total of 128 tumors were identified in the 68 affected individuals. The 128 tumor sites were as follows: breast, 25; bones, 16; brain, 12; hematological, 11; soft tissues, 10; stomach, 10; lung, 10; colorectum, 10; adrenal gland, 9; liver, 4; and others, 11. Unique phenotype patterns of LFS were shown in Japan in comparison with those in a large national LFS cohort study in France. Above all, a higher frequency of patients with stomach cancer was observed in Japanese TP53 germline variant carriers. These results may provide useful information for the clinical management of LFS in Japan.

7 October 2019 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
T(The Japanese Society For Cancer Of The Colon And Rectum (Jsccr)
The Japanese Society For Cancer Of The Colon And Rectum (Jsccr)
TITsuneo Ikenoue
Tsuneo Ikenoue
MAMasami Arai
Masami Arai
CIChikashi Ishioka
Chikashi Ishioka
TITakeo Iwama
Takeo Iwama
YFYoichi Furukawa
Yoichi Furukawa

6 May 2021 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
KYKiyoshi Yamaguchi
Kiyoshi Yamaguchi
RKRika Kasajima
Rika Kasajima
KTKiyoko Takane
Kiyoko Takane
SHSeira Hatakeyama
Seira Hatakeyama
ESEigo Shimizu
Eigo Shimizu
TITsuneo Ikenoue
Tsuneo Ikenoue

24 May 2012 in Oncology Reports
Verified
Journal Article
Open access
PDF file
TKTakashi Kuno
Takashi Kuno
NMNagahide Matsubara
Nagahide Matsubara
STSatoshi Tsuda
Satoshi Tsuda
MKMasayoshi Kobayashi
Masayoshi Kobayashi
MHMie Hamanaka
Mie Hamanaka
NTNaohiro Tomita
Naohiro Tomita
The base excision repair gene MUTYH encodes glycosylase which removes adenine residues mispaired with 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-OHG). Biallelic germline mutations of the MUTYH gene are known to cause multiple colorectal adenomas including polyposis and cancer, mostly due to G:C -> T:A transversions in proto-oncogenes or tumor suppressor genes. The risk of colorectal cancer (CRC) in monoallelic mutation carriers of MUTYH is estimated to be higher in comparison with non-carriers. To investigate the possible role in sporadic CRC, we examined alterations of the MUTYH gene including somatic mutations and allelic loss in 101 cases of sporadic CRC, together with the KRAS mutation in some cases. MUTYH mutations in cancer DNA were detected in 3 cases, while mutations were also found in DNA samples from normal tissues, indicating that all were germline mutations. Allelic loss at the MUTYH locus was found in 10 of 51 (20.0%) CRC cases and KRAS mutations were found in 33 of the 101 (32.7%) samples. There was no significant difference in the rate of G:C -> T:A transversion in KRAS between cases with allelic loss (1 of 10, 10.0%) and without allelic loss (9 of 41, 22.0%). Investigation of quantitative allelic imbalance at SNP rs3219489 of MUTYH showed that CRC cases with C allele dominance (minor type corresponding to His) were more frequently detected with G:C -> T:A transversions than in those with G allele dominance (major type corresponding to Gln). In conclusion, somatic alterations of MUTYH in sporadic CRC were rare, similar to other DNA repair genes. However, it is possible that unknown mutations of regions not analyzed in this study and epigenetic changes of the promoter region of MUTYH may contribute to the disease.